Revenue: As of FY2026 Q2, the actual value is USD 119.22 M, missing the estimate of USD 121.04 M.

EPS: As of FY2026 Q2, the actual value is USD 1.79, beating the estimate of USD 1.6275.

EBIT: As of FY2026 Q2, the actual value is USD 66.08 M.

The provided reference, a Form 8-K filing by Krystal Biotech, Inc., announces the release of its financial results for the quarter ending June 30, 2026, on August 3, 2026 . However, the actual financial results, operational metrics, or outlook/guidance are not included within this document . These details are referenced as being in an attached Exhibit 99.1, which is not provided in the reference text . Therefore, no financial or operational metrics, nor any outlook or guidance, can be extracted from the given text .